New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people li

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. MU
6. FDX
7. IBM
8. PRIM
9. PFE
10. AWK

Go back to New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people li
(NASDAQ: ZEAL) Delayed: 17.59 --0 (-0%)
Previous Close $17.59    52 Week High $ 
Open $1.35    52 Week Low $ 
Day High $17.59    P/E N/A 
Day Low $17.59    EPS $ 
Volume 15,962       

(NASDAQ: ZEAL) Delayed: 17.59 --0 (-0%)
Previous Close $17.59    52 Week High $ 
Open $1.35    52 Week Low $ 
Day High $17.59    P/E N/A 
Day Low $17.59    EPS $ 
Volume 15,962